Other studies have also reported the CDKN2A/B homozygous deletion to be associated with unfavorable outcomes for all IDH‐mutant astrocytoma grades (WHO grades II–IV) and IDH‐wildtype GBM.19, 20, 21. Here, CDKN2A is linked to astrocytoma (excluding glioblastoma).